Price T Rowe Associates Inc Madrigal Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

$869 Billion
Q3 2024

A detailed history of Price T Rowe Associates Inc transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 733,697 shares of MDGL stock, worth $253 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

733,697

Previous 858,765 14.56%

Holding current value

$253 Million

Previous $241 Million 35.28%

% of portfolio

0.02%

Previous 0.03%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$212.22 - $292.96 $26.5 Million - $36.6 Million	-125,068 Reduced 14.56%	733,697 $156 Million
Q2 2024 Aug 14, 2024	BUY	$193.33 - $291.99 $10.7 Million - $16.2 Million	55,552 Added 6.92%	858,765 $241 Million
Q1 2024 May 15, 2024	BUY	$171.37 - $283.23 $71 Million - $117 Million	414,484 Added 106.63%	803,213 $214 Million
Q4 2023 Feb 14, 2024	BUY	$120.4 - $237.13 $26.3 Million - $51.8 Million	218,356 Added 128.16%	388,729 $89.9 Million
Q3 2023 Nov 14, 2023	BUY	$146.04 - $225.78 $16.8 Million - $26 Million	114,970 Added 207.52%	170,373 $24.9 Million
Q2 2023 Aug 14, 2023	BUY	$203.88 - $312.0 $1.71 Million - $2.62 Million	8,403 Added 17.88%	55,403 $12.8 Million
Q1 2023 May 15, 2023	SELL	$231.06 - $307.08 $1.91 Million - $2.53 Million	-8,250 Reduced 14.93%	47,000 $11.4 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $503,847 - $2.56 Million	8,629 Added 18.51%	55,250 $16 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $255,544 - $335,452	4,219 Added 9.95%	46,621 $3.03 Million
Q2 2022 Aug 15, 2022	SELL	$58.04 - $100.2 $144,925 - $250,199	-2,497 Reduced 5.56%	42,402 $3.04 Million
Q1 2022 May 16, 2022	SELL	$55.89 - $101.89 $198,633 - $362,117	-3,554 Reduced 7.33%	44,899 $4.41 Million
Q4 2021 Feb 14, 2022	SELL	$72.34 - $95.09 $676,161 - $888,806	-9,347 Reduced 16.17%	48,453 $4.11 Million
Q3 2021 Nov 15, 2021	SELL	$78.35 - $105.02 $1.45 Million - $1.94 Million	-18,455 Reduced 24.2%	57,800 $4.61 Million
Q2 2021 Aug 16, 2021	SELL	$97.2 - $137.59 $902,599 - $1.28 Million	-9,286 Reduced 10.86%	76,255 $7.43 Million
Q1 2021 May 17, 2021	SELL	$108.54 - $125.2 $9.3 Million - $10.7 Million	-85,668 Reduced 50.04%	85,541 $10 Million
Q4 2020 Feb 16, 2021	BUY	$110.06 - $133.7 $18.8 Million - $22.9 Million	171,209 New	171,209 $19 Million

Others Institutions Holding MDGL

# of Institutions

298

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.9B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Madrigal Pharmaceuticals, Inc. Transaction History